Coherus Biosciences Inc (CHRS) Is Looking To Compete With Amgen, Inc. (AMGN)’s Cancer Blockbuster
The biosimilar space is relatively young.
Charming Shoppes Inc (CHRS)
Market is closed
News
- First
- << Previous
- 31 - 37
Why Coherus Biosciences, Hortonworks and 3 Other Stocks Are Posting Big Gains Today
The markets are off to a rocking start this week on the back of growing optimism after a strong jobs report on Friday, and waning uncertainty around the global economy after Japanese Prime Minister Shinzo...
13G Filing: Healthcare Royalty Partners III, L.p. and Coherus Biosciences, Inc. (CHRS)
The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information...
Venrock's VHCP Management's Top Picks For 2016
At Insider Monkey, we look at the weighted average returns of the long positions a fund indicates in its 13F filings, in companies with a market cap greater than $1 billion, to estimate the returns of...
Why Are Investors Spooked About These 4 Stocks Today?
With many market participants on edge given the impending FOMC meeting next week and the plunging crude prices, shares of Kite Pharma Inc (NASDAQ:KITE), Qunar Cayman Islands Ltd (NASDAQ:QUNR), Coherus...
Here Is What Hedge Funds Think Of Coherus Biosciences Inc (CHRS)
We at Insider Monkey have gone over 700 13F filings that hedge funds and prominent investors are required to file by the government.
JUNO Therapeutics Inc (JUNO); Coherus Biosciences Inc (CHRS), Stemline Therapeutics Inc (STML): VCHP's Bullish Sentiment Pays Off
Juno Therapeutics Inc (NASDAQ:JUNO) is up by 15% as of Thursday afternoon, following the release of its first-ever earnings report since its IPO.
- First
- << Previous
- 31 - 37
Billionaire Hedge Funds
